Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.
2.

Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.

Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators..

JAMA Intern Med. 2013 Oct 14;173(18):1682-92.

PMID:
23939297
3.

Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.

Howlett TA, Willis D, Walker G, Wass JA, Trainer PJ; UK Acromegaly Register Study Group (UKAR-3)..

Clin Endocrinol (Oxf). 2013 Nov;79(5):689-99. doi: 10.1111/cen.12207. Epub 2013 Apr 24.

PMID:
23574573
4.

Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE).

Han TS, Krone N, Willis DS, Conway GS, Hahner S, Rees DA, Stimson RH, Walker BR, Arlt W, Ross RJ; United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE)..

Eur J Endocrinol. 2013 May 3;168(6):887-93. doi: 10.1530/EJE-13-0128. Print 2013 Jun.

5.

Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia.

Han TS, Stimson RH, Rees DA, Krone N, Willis DS, Conway GS, Arlt W, Walker BR, Ross RJ; United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE)..

Clin Endocrinol (Oxf). 2013 Feb;78(2):197-203. doi: 10.1111/cen.12045.

PMID:
22998134
6.

Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study.

Pfister R, Cairns R, Erdmann E, Schneider CA; PROactive investigators..

Diabet Med. 2011 Oct;28(10):1206-12. doi: 10.1111/j.1464-5491.2011.03281.x.

PMID:
21388447
7.

Effect of oral phosphate and alendronate on bone mineral density when given as adjunctive therapy to growth hormone replacement in adult growth hormone deficiency.

White HD, Ahmad AM, Durham BH, Joshi AA, Fraser WD, Vora JP.

J Clin Endocrinol Metab. 2011 Mar;96(3):726-36. doi: 10.1210/jc.2010-1929. Epub 2011 Jan 20.

PMID:
21252245
8.

Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients.

Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, Han TS, Carroll PV, Conway GS, Rees DA, Stimson RH, Walker BR, Connell JM, Ross RJ; United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE)..

J Clin Endocrinol Metab. 2010 Nov;95(11):5110-21. doi: 10.1210/jc.2010-0917. Epub 2010 Aug 18.

9.

Correlation of serum-adjusted calcium with ionized calcium over a 24-h period in patients with adult growth hormone deficiency before and after growth hormone replacement.

White HD, Joshi AA, Ahmad AM, Durham BH, Vora JP, Fraser WD.

Ann Clin Biochem. 2010 May;47(Pt 3):212-6. doi: 10.1258/acb.2010.009178. Epub 2010 Apr 14.

PMID:
20392749
10.

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators..

Am J Kidney Dis. 2009 Nov;54(5):810-9. doi: 10.1053/j.ajkd.2009.03.022. Epub 2009 Jun 21.

PMID:
19540640
11.

Endocrine evaluation of pituitary tumours.

Saunders S, Vora JP.

Br J Neurosurg. 2008 Aug;22(4):602-8. doi: 10.1080/02688690802385974.

PMID:
18803082
12.

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators., Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P.

Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Erratum in: Lancet. 2008 Oct 18;372(9647):1384.

PMID:
18757085
13.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

ONTARGET Investigators., Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C.

N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31.

14.

Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.

Joseph F, Ahmad AM, Ul-Haq M, Durham BH, Whittingham P, Fraser WD, Vora JP.

J Bone Miner Res. 2008 May;23(5):721-9.

15.

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive Investigators..

Diabetes Care. 2007 Nov;30(11):2773-8. Epub 2007 Jul 31.

PMID:
17666462
16.

PTH circadian rhythm and PTH target-organ sensitivity is altered in patients with adult growth hormone deficiency with low BMD.

White HD, Ahmad AM, Durham BH, Peter R, Prabhakar VK, Corlett P, Vora JP, Fraser WD.

J Bone Miner Res. 2007 Nov;22(11):1798-807.

17.

The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion.

Joseph F, Chan BY, Durham BH, Ahmad AM, Vinjamuri S, Gallagher JA, Vora JP, Fraser WD.

J Clin Endocrinol Metab. 2007 Aug;92(8):3230-8. Epub 2007 Jun 5.

PMID:
17550963
18.

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators..

J Am Coll Cardiol. 2007 May 1;49(17):1772-80. Epub 2007 Apr 16.

19.

Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity.

White HD, Ahmad AM, Durham BH, Chandran S, Patwala A, Fraser WD, Vora JP.

J Clin Endocrinol Metab. 2006 Mar;91(3):913-9. Epub 2005 Dec 13.

PMID:
16352693
20.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators..

Lancet. 2005 Oct 8;366(9493):1279-89.

PMID:
16214598

Supplemental Content

Loading ...
Support Center